Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 20/20 | 0.89 |
| ▸ | ADRA1D | P25100 | 17/20 | 0.89 |
| ▸ | ADRA1B | P35368 | 17/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 15/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 15/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 15/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453007 | 1.00 | ADRA1A (0.89) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL5165068 | 0.93 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL5919546 | 0.93 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7033291 | 0.91 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL8330956 | 0.82 | ADRA1A (0.68) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL28941106 | 0.81 | ADRA1A (0.59) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL7237529 | 0.81 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL8537000 | 0.80 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| SCHEMBL31061130 | 0.78 | ADRA1A (0.85) | ADRA1AADRA1DADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL7240209 | 0.78 | ADRA1A (0.85) | ADRA1AADRA1DADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | ADRA1A 9/4885ADRA1D 11/4885ADRA1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.